Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety,
tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when
replacing standard combination therapy in HIV-infected patients with prolonged virological
suppression